Welcome to our dedicated page for Penumbra news (Ticker: PEN), a resource for investors and traders seeking the latest updates and insights on Penumbra stock.
Penumbra, Inc. (NYSE: PEN) is described in its public communications as the world’s leading thrombectomy company, with a portfolio focused on computer assisted vacuum thrombectomy (CAVT™) and related devices for serious vascular and neurovascular conditions. The Penumbra news feed on this page aggregates company announcements, clinical trial updates and capital markets communications that shape how investors and clinicians follow the PEN stock story.
Recent news includes the announcement of a definitive Agreement and Plan of Merger with Boston Scientific Corporation, under which a Boston Scientific subsidiary will merge with and into Penumbra, leaving Penumbra as a wholly owned subsidiary if the transaction closes. The joint press release details the planned cash-and-stock consideration and notes that, upon completion, Penumbra’s securities are expected to be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934.
Beyond M&A developments, Penumbra’s news flow features earnings releases and preliminary financial updates furnished via Form 8-K, outlining revenue trends, margins and non-GAAP measures such as constant currency revenue and adjusted EBITDA. These items provide context on the company’s operating performance and financial outlook as it continues to develop and commercialize thrombectomy and embolization technologies.
Penumbra also issues news around clinical research milestones. Notable examples include results from the pivotal STORM-PE randomized controlled trial, which evaluated CAVT using Penumbra’s Lightning Flash™ plus anticoagulation versus anticoagulation alone in acute intermediate-high risk pulmonary embolism. Company press releases describe superior reductions in right heart strain, thrombus burden and improvements in functional outcomes for patients treated with CAVT plus anticoagulation, with comparable safety profiles between treatment arms.
Additional news items cover leadership changes and investor relations activities, such as the appointment of a new company president and scheduled presentations at healthcare and investor conferences, including the J.P. Morgan Healthcare Conference and other sector events. These updates highlight how Penumbra’s management communicates with the investment community and discusses its clinical and commercial strategy.
By following this PEN news page, readers can review a consolidated stream of Penumbra’s press releases, transaction announcements, clinical trial disclosures and financial updates, all of which are sourced from official company communications and SEC-related materials.
Penumbra, Inc. (NYSE: PEN) has announced a conference call to discuss its financial results for Q1 2021, scheduled for May 4, 2021, at 4:30 PM ET. The results will be released after market close on the same day. Investors can join the call by dialing (833) 350-1434 or accessing the webcast on the company’s website. Further information about Penumbra, a global healthcare company focused on innovative therapies, can be found on its website.
Penumbra, Inc. (NYSE: PEN) has launched the Indigo® System Lightning™ 7, enhancing its Indigo Aspiration System for arterial thrombus removal. This new device combines the CAT™7 Aspiration Catheter with Lightning Intelligent Aspiration technology, enabling effective single-session clot extraction. Key features include optimized thrombus detection and reduced blood loss. CEO Adam Elsesser emphasized the technology's potential to improve patient outcomes and reduce ICU demands. The Indigo System is indicated for treating fresh emboli and thrombi in peripheral vessels and pulmonary embolism.
Penumbra, Inc. (NYSE: PEN) reported its fourth quarter and full-year financial results for 2020, revealing a 14.9% increase in quarterly revenue to $166.9 million and a full-year revenue of $560.4 million, up 2.4% year-over-year. Excluding a voluntary recall, quarterly revenue was $172.7 million, an 18.9% rise. However, a 6.6% decline in neuro product sales was noted. Operating loss for the fourth quarter stood at $1.7 million, but excluding one-time impacts, non-GAAP operating income was $16.6 million. For 2021, Penumbra projects revenue growth of 20% to 22%.
Penumbra, Inc. (NYSE: PEN) announced its management team will present at Citi's 2021 Healthcare Services, Medtech, Tools, & HCIT Virtual Conference on February 24, 2021, at 3:20 PM ET. The event aims to showcase innovative therapies and products developed by Penumbra.
A webcast of the presentation will be accessible on their website for at least two weeks post-event. Penumbra, headquartered in Alameda, California, specializes in innovative medical solutions, catering to significant unmet healthcare needs.
Penumbra, Inc. (NYSE: PEN) announced a conference call to discuss its fourth quarter and full year 2020 financial results scheduled for February 23, 2021 at 4:30 PM ET. A press release will be issued after market close that day detailing the financial metrics. The call can be accessed via phone or live webcast on the company's website. Penumbra focuses on innovative therapies, selling products to hospitals and healthcare providers in various regions, including the U.S. and Europe.
Penumbra, Inc. (NYSE: PEN) released preliminary revenue results for Q4 and FY 2020, highlighting a projected fourth quarter revenue of $162.5 to $167.9 million, reflecting a 12% to 16% increase year-over-year. Excluding a voluntary recall impact, non-GAAP revenue for Q4 is estimated at $172.5 to $172.9 million, a 19% growth. Full-year revenue is expected between $556.0 and $561.4 million, up 2% to 3% from 2019. Vascular product sales are projected to grow significantly, while neuro product sales are estimated to decline by 11% to 13% for the year.
Penumbra recalls JET 7 Xtra Flex Catheters on December 15, 2020, due to susceptibility to distal tip damage. This issue may lead to potential vessel damage and serious patient injury or death during use. The company advises healthcare professionals to review the full recall advisory on their website. They will also hold a conference call on the same day to discuss details surrounding this voluntary recall, which could impact their market reputation and financial stability.
On December 8, 2020, Penumbra, Inc. (NYSE: PEN) issued a statement addressing false claims made by short sellers regarding scientific research by co-founder Dr. Arani Bose. The company confirmed that allegations about misattributed research are inaccurate. CEO Adam Elsesser spoke with Bank of America analyst Bob Hopkins, reaffirming the integrity of the Penumbra JET 7 Reperfusion Catheter and emphasizing compliance with Quality System Regulations. Penumbra reported no patient deaths linked to the catheter when used properly and is considering further actions against the allegations.
Penumbra, Inc. (NYSE: PEN) has announced that its CEO will participate in a discussion with Bank of America on December 8, 2020, at 8:30 AM ET. The event will focus on the company's innovative healthcare therapies. An audio webcast will be accessible on the company’s website for at least two weeks post-event. Based in Alameda, California, Penumbra specializes in developing and marketing products addressing significant medical needs in healthcare markets worldwide.
Penumbra, Inc. (NYSE: PEN) received FDA 510(k) clearance for the expanded indications of its Indigo® Aspiration System, including the Lightning™ 12 catheter. This system is now approved for removing fresh emboli and thrombi from peripheral arteries and veins, and for treating pulmonary embolism (PE), a condition that has risen during the COVID-19 pandemic. Lightning 12's advanced technology improves clot detection and removal efficacy. The system was launched in July and is available for immediate use, aiming to reduce the need for thrombolytics and associated ICU stays.
FAQ
What is the current stock price of Penumbra (PEN)?
What is the market cap of Penumbra (PEN)?
